339185-69-2 Usage
Uses
Used in Pharmaceutical Research:
[2-(3-BROMO-PHENYL)-2-OXO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER is used as a building block for the synthesis of pharmaceutical compounds due to its unique functional groups that facilitate the creation of diverse medicinal agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, [2-(3-BROMO-PHENYL)-2-OXO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER serves as a research tool, enabling scientists to explore its potential in the development of new drugs and therapeutic agents.
Used in Drug Development:
[2-(3-BROMO-PHENYL)-2-OXO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER is employed in drug development processes to enhance the discovery and optimization of novel pharmaceuticals, capitalizing on its molecular structure and properties to improve therapeutic efficacy and safety.
Used in Chemical Synthesis Industry:
[2-(3-BROMO-PHENYL)-2-OXO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER is used as a key intermediate in the synthesis of various organic compounds, contributing to the advancement of chemical manufacturing and the production of specialty chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 339185-69-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,9,1,8 and 5 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 339185-69:
(8*3)+(7*3)+(6*9)+(5*1)+(4*8)+(3*5)+(2*6)+(1*9)=172
172 % 10 = 2
So 339185-69-2 is a valid CAS Registry Number.
339185-69-2Relevant academic research and scientific papers
PRO-DRUGS OF TERTIARY ALCOHOLS
-
Page/Page column 45-46, (2008/06/13)
The compounds of the present invention are prodrugs of modulators of the Cannabinoid-1 (CB 1 ) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the Cannabinoid- 1 (CB 1) receptor. In particular, compounds of the
SUBSTITUTED ARYL AMIDES
-
Page/Page column 69-70, (2010/02/07)
Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
